头孢哌酮/舒巴坦治疗胆道感染的前瞻性、多中心临床研究  

Cefoperazone/sulbactam in Treatment of Biliary Tract Infections:A Prospective Multicenter Clinical Trial

作　　者：黎沾良[1] 张同琳[2] 徐智[2] 杨磊[3] 刘家峰[3] 梁力建[4] 赖佳明[4] 张平[5] 彭承宏[6] 陈皓[6] 全志伟[7] 张生来[7] 梁庭波[8] 王伟林[8] 蒋飞照[9] 张志伟[10] 张必翔[10] 崔乃强[11] 傅强[11] 李强[12] 谢敏[12] 

机构地区：[1]解放军总医院第一附属医院普通外科,北京100037 [2]北京医科大学第三医院普通外科,北京100083 [3]北京宣武医院普通外科,北京100053 [4]中山医科大学附属第一医院肝胆外科,广东广州510080 [5]中国医科大学附属第一医院外科,辽宁沈阳110001 [6]上海第二医科大学附属瑞金医院外科,上海200025 [7]上海第二医科大学附属新华医院外科,上海200092 [8]浙江大学医学院附属第一医院外科,浙江杭州310003 [9]温州医学院附属第一医院外科,浙江温州325000 [10]武汉同济医院外科,湖北武汉430030 [11]天津南开医院外科,天津300010 [12]南京大学鼓楼医院外科,江苏南京210008

出　　处：《中华医院感染学杂志》2008年第4期552-555,共4页Chinese Journal of Nosocomiology

摘　　要：目的研究头孢哌酮/舒巴坦治疗胆道感染的临床疗效和安全性。方法前瞻性、多中心研究159例确诊为胆道感染并接受头孢哌酮/舒巴坦治疗的住院患者,评价其临床疗效、细菌学疗效与不良反应。结果头孢哌酮/舒巴坦治疗胆道感染的临床有效率为86.78%;患者经治疗后发热迅速缓解,平均退热时间(3.09±1.81)d;头孢哌酮/舒巴坦治疗的细菌学清除率为85.71%;研究中无不良反应发生。结论头孢哌酮/舒巴坦可作为经验性治疗胆道感染的首选药物之一。OBJECTIVE To evaluate the safety and clinical efficacy of cefoperazone/sulbactam in the treatment of biliary tract infections.METHODS In this prospective multicenter study,159 hospitalized patients with biliary tract infections received cefoperazone/sulbactam,and the clinical and bacteriological efficacy as well as the side effects were evaluated.RESULTS The clinical effective rate of cefoperazone/sulbactam in the treatment of biliary tract infections was 86.78%.After treatment,the body temperature reduced to normal rapidly,the average time of defervescence was 3.09±1.81 days.Pathogen eradication rate was 85.71%.No adverse reactions were reported during the study period.CONCLUSIONS Cefoperazone/sulbactam can be used as one of antibiotics of choice in the initial empirical therapy for biliary tract infections.

关 键 词：胆道感染 头孢哌酮/舒巴坦 治疗 

分 类 号：R978.11[医药卫生—药品]